Synthetech Part of Grace

Synthetech Profile

Home | Products | Profile | Capabilities

Profile

Grace Acquisition
On November 18 2011, Grace acquired Synthetech Inc. Synthetech’s expertise in organic synthesis and biocatalysis provided Grace with synergistic capabilities and additional capacity for the manufacture of specialty single-site and polypropylene catalysts used in the production of plastics.

In addition, the acquisition complements Grace’s Discovery Sciences product portfolio and broadens the solutions we can offer our customers in the pharmaceutical discovery through development, formulation, and manufacturing.

Facility

Our kilo lab and pilot plant provide the scale-up facilities to enable us to efficiently implement a commercial manufacturing process while supplying developmental quantities throughout clinical trials.	Product isolation is carried out using centrifuges and filter presses. Centrifuges range in diameter from 32 to 48 inches. Plate and frame filter presses are available in polypropylene and stainless steel, and range in size from 18 to 30 inches. In addition, assorted vacuum and pressure nutsche filters and jacketed sparkler filters are utilized.
The new wastewater treatment facility allows us to meet new regulatory requirements.	Drying equipment includes several vacuum tray dryers ranging in size from 40 to 128 square feet. Additional drying capabilities include a 10 cubic foot cone dryer and an 80 cubic foot rotary vacuum dryer.
Our total commitment to safety and environmental controls is reflected in the state-of-the-art design features of the tank farm and unloading station, which prevent and contain accidental spills and releases.	Sophisticated analytical instrumentation can detect parts-per-billion levels of regulated pollutants in industrial wastewater effluent.

Safety
As a manufacturer of fine chemicals/intermediates and an Oregon OSHA Safety and Health Recognition Achievement Program (SHARP) company, our goal is to promote a safe and secure work environment and to ensure that all operations and activities are in compliance with departmental, agency, state and federal regulations and guidelines, and to protect our assets and property in a secure manner. We are proud to be a recipient of the prestigious SOCMA safety award for 5 consecutive years and remain committed to maintaining a strong Environmental, Health, Safety and Security (EHS&S) program.

Quality
We continue to be committed to delivering high-quality products to our customers. To ensure that our customers' quality expectations are met, we have developed a comprehensive cGMP environment for manufacturing large-scale advanced intermediates and early-phase APIs. This promotes manufacture of superior pharmaceutical intermediates and ensures that our final products are consistently delivered on time and within specification. Several recent customer audits have resulted in cGMP intermediate and early-phase API qualification.

History

2010	November 18 2010, Grace acquires Synthetech
2006	Synthetech acquires Peptide Resin Technology from Colorado Biotech and enters the SPPS resin arena as the sole large scale US manufacturer.
2004	Roche Designates Synthetech as 2003 Raw Materials Vendor of the Year
2003	In March 2003, remodel of 1,300 square foot Quality Control Department completed. In April 2003, Synthetech achieved recognition from Oregon OSHA Safety and Health Recognition Program (SHARP). The prestigious SHARP award recognizes those employers in Oregon who have achieved an exemplary level of occupational safety and health management.
2002	In July 2002, Synthetech purchased and added improvements to an office and warehouse facility adjacent to its production facilities. The new building contains 1,700 square feet of office space and approximately 3,000 square feet of warehouse space.
2001	Fiscal 2001 saw the addition and upgrades of equipment in the existing plant and completion of the second phase of the new plant expansion. The R&D expansion and remodel was completed in April 2001 and the on-site wastewater treatment facility came on-line in September 2001.
1999	Revenues exceed $20 million in Fiscal 1999 ended March 31, 1999. 10th consecutive year of profitable operations. Phase II of plant expansion in progress.
1998	First commercial multi-ton orders for approved drugs. First Phase of new large-scale facility in operation.
1997	Tenth year of manufacturing operation Completed Phase I of new large-scale facility. Revenues exceed $10 million in FY 1997 ended March 31, 1997. Ranked among "200 Hot Growth Companies" by Business Week magazine. Ranked among "Oregon Technology Fast 50" sponsored by Oregon Business magazine, Deloitte & Touche LLP, Pacific Crest Securities, and Tonkon Torp Galen Marmaduke & Booth.
1996	Began plant expansion. Stock moved to National Market System from Nasdaq's Small-Cap listings. Ranked among "200 Best Small Companies" by Forbes magazine and the "100 Hottest Small Companies" by Financial World magazine. Oregon Technology Company of the Year Award- Cascade Pacific Council.
1995	Technology Entrepreneur of the Year, Oregon Enterprise Forum Arcturus (Rising Star) award from Oregon Business magazine.
1994	Top 50 in Oregon/SW Washington (The Oregonian) Ranked second in Seattle Times Northwest 100. Fifth continuous year of growth and profitability.
1993	Ranked nationally as a leading small public company: Inc. 100 based on five-year sales growth rate. Northwest 100 (SeattleTimes) based on two-year financial performance.
1987	Acquired manufacturing facility in Albany, Oregon. Began multi-kilo production of Specialty Amino Acids.
1984	Initial public offering: shares traded on Nasdaq under symbol.
1981	Synthetech founded in Boulder, Colorado

Home | Products | Profile | Capabilities